Investopedia: Biogen Idec Has Built A Valuable Franchise

Diversification is all well and good, but there's nothing wrong with a well-run company that does a few things very well. With an enviable franchise in multiple sclerosis, a promising pipeline and a host of pharmaceutical giants desperate for growth and operating leverage, Biogen Idec (Nasdaq:BIIB) could yet have a few surprises left for shareholders.

Steady Progress in Q3 
Third quarter results did not have a lot of financial surprises, but Biogen Idec continues to grow nicely. Total revenue rose 11%, with Tysabri, which the company sells in partnership with Elan (NYSE:ELN), growing 26% and key drug Avonex showing 6% sales growth. Although Avonex seems to be showing some wear with Novartis's (NYSE:NVS) drug Gilenya on the market, it still represents over half of the company's sales.

Read the full article here:
http://stocks.investopedia.com/stock-analysis/2011/Biogen-Idec-Has-Built-A-Valuable-Franchise-BIIB-ELN-NVS-DGX-MKGAY.PK-TEVA-SNY-PFE1101.aspx